Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
NCT03591666Phase 2Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Adenocarcinoma of the head and neck, sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Adenocarcinoma of the head and neck
Beyond the preview
Go deeper on NCT03591666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591666.